UCLA-led study finds delivering high doses of radiation with chemotherapy for locally advanced lung cancer is safe and effective when integrating a novel adaptive boost A new study led by researchers ...

An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in ...

Adding an intermediate-dose stereotactic ablative radiotherapy (SABR) boost of TKGy to hypofractionated concurrent chemoradiation appears safe and improves outcomes in patients with unresectable, ...